Literature DB >> 2371778

Differences in replication and cytopathogenicity of human immunodeficiency virus type 1 (HIV-1) are not determined by long terminal repeats (LTR).

I Hirsch1, B Spire, Y Tsunetsugu-Yokota, C Neuveut, J Sire, J C Chermann.   

Abstract

The growth properties of molecular clones of a highly cytopathic Zairian HIV1-NDK and prototype viruses were compared to correlate genetic variations with biological changes. The cloned HIV1-NDK retained the highly replicating cytopathic phenotype and formed larger syncytia than the prototype. One of the major differences in the alignment of the nucleotide sequence of the HIV1-NDK and HIV1-BRU prototypes was localized in the negative regulatory element (NRE) of the long terminal repeat (LTR). In a chloramphenicol acetyl transferase (CAT) assay, we failed to detect a significant difference between LTR promoter activity of the prototype and HIV1-NDK, suggesting that the LTR of both phenotypes had a similar function. The complete recombinant provirus DNA molecules bearing HIV1 LTR derived from one phenotype and the rest of the genomes from the other phenotype were constructed and transfected. The high cytopathogenicity of both the original and the chimeric viruses was correlated with the high speed of virus replication. Cytopathogenicity, morphology of syncytia, and replication kinetics of the recombinant viruses were determined by the functions coded within an internal part of HIV1 genome, covering the gag to env region, which were, however, not within LTR.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2371778     DOI: 10.1016/0042-6822(90)90544-2

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  8 in total

1.  Generation of hybrid human immunodeficiency virus utilizing the cotransfection method and analysis of cellular tropism.

Authors:  A Velpandi; T Nagashunmugam; S Murthy; M Cartas; C Monken; A Srinivasan
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

2.  Structural variability of env and gag gene products from a highly cytopathic strain of HIV-1.

Authors:  N Yahi; J Fantini; I Hirsch; J C Chermann
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

3.  Genetic differences accounting for evolution and pathogenicity of simian immunodeficiency virus from a sooty mangabey monkey after cross-species transmission to a pig-tailed macaque.

Authors:  V Courgnaud; F Lauré; P N Fultz; L Montagnier; C Bréchot; P Sonigo
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

4.  Structural and functional evolution of human immunodeficiency virus type 1 long terminal repeat CCAAT/enhancer binding protein sites and their use as molecular markers for central nervous system disease progression.

Authors:  Tricia H Hogan; Devin L Stauff; Fred C Krebs; Suzanne Gartner; Shane J Quiterio; Brian Wigdahl
Journal:  J Neurovirol       Date:  2003-02       Impact factor: 2.643

5.  Changes in both gp120 and gp41 can account for increased growth potential and expanded host range of human immunodeficiency virus type 1.

Authors:  K Fujita; J Silver; K Peden
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

6.  The human immunodeficiency virus (HIV) gag gene product p18 is responsible for enhanced fusogenicity and host range tropism of the highly cytopathic HIV-1-NDK strain.

Authors:  J de Mareuil; B Brichacek; D Salaun; J C Chermann; I Hirsch
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

7.  Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps.

Authors:  M Courcoul; C Patience; F Rey; D Blanc; A Harmache; J Sire; R Vigne; B Spire
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

8.  An antibody that binds the immunoglobulin CDR3-like region of the CD4 molecule inhibits provirus transcription in HIV-infected T cells.

Authors:  M Benkirane; P Corbeau; V Housset; C Devaux
Journal:  EMBO J       Date:  1993-12-15       Impact factor: 11.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.